

Product Information Sheet for NR-51619

Monoclonal Anti-Venezuelan Equine Encephalitis Virus, PTF-39 (Subtype IB) E2 Glycoprotein Antibody, Clone 1A3B-7

Catalog No. NR-51619

This reagent is the property of the U.S. Government.

For research use only. Not for human use.

Contributor:

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Maryland, USA

Product Description:

Antibody Class: IgG2ak

Mouse monoclonal antibody prepared against the E2 glycoprotein of Venezuelan equine encephalitis (VEE) virus, PTF-39 (subtype IB) was purified from clone 1A3B-7 hybridoma supernatant by protein A-Sepharose chromatography. The B cell hybridoma was generated by the fusion of Sp2/0-Ag14 myeloma cells with mouse splenocytes immunized with purified, inactivated VEE virus, strain PTF-39.¹ The clone 1A3B-7 antibody is reported to be specific for VEE E2 glycoprotein and has protective effects in a murine model against aerosol exposure to VEE virus from serotype I, II and III.¹.²

Material Provided:

Each vial of NR-51619 contains approximately 100 μ L of purified monoclonal antibody in Dulbecco's phosphate buffered saline (D-PBS). The concentration, expressed as mg per mL, is shown on the Certificate of Analysis.

Packaging/Storage:

NR-51619 was packaged aseptically in screw-capped plastic vials and is provided frozen on dry ice. The product should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be avoided.

Functional Activity:

NR-51619 is neutralizing and was shown to be reactive in ELISA and hemagglutination assays.¹

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-Venezuelan Equine Encephalitis Virus, PTF-39 (Subtype IB) E2 Glycoprotein Antibody, Clone 1A3B-7, NR-51619."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed.

Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

- Roehrig, J. T. and J. H. Mathews. "The Neutralization Site on the E2 Glycoprotein of Venezuelan Equine Encephalomyelitis (TC-83) Virus is Composed of Multiple Conformationally Stable Epitopes." <u>Virology</u> 142 (1985): 347-356. PubMed: 2414905.
- Phillpotts, R. J. "Venezuelan Equine Encephalitis Virus Complex-Specific Monoclonal Antibody Provides Broad Protection, in Murine Models, Against Airborne Challenge with Viruses from Serogroups I, II and III." <u>Virus Res.</u> 120 (2006): 107-112. PubMed: 16621103.

 $\mathsf{ATCC}^{\circledcirc}$ is a trademark of the American Type Culture Collection.

Support Provided by NIAID

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898